These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22223499)

  • 1. [A challenge towards the clinical application of induced pluripotent stem cell technology for the treatment of Parkinson's disease].
    Morizane A; Takahashi J
    Brain Nerve; 2012 Jan; 64(1):29-37. PubMed ID: 22223499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems.
    Hwang DY; Kim DS; Kim DW
    J Cell Biochem; 2010 Feb; 109(2):292-301. PubMed ID: 20014069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells.
    Fung RK; Kerridge IH
    Bioethics; 2013 Feb; 27(2):89-96. PubMed ID: 21726264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced pluripotent stem cell research: a revolutionary approach to face the challenges in drug screening.
    Song M; Paul S; Lim H; Dayem AA; Cho SG
    Arch Pharm Res; 2012 Feb; 35(2):245-60. PubMed ID: 22370779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem cell therapy for Parkinson's disease.
    Takahashi J
    Expert Rev Neurother; 2007 Jun; 7(6):667-75. PubMed ID: 17563250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling human neurological disorders with induced pluripotent stem cells.
    Imaizumi Y; Okano H
    J Neurochem; 2014 May; 129(3):388-99. PubMed ID: 24286589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restorative approaches in Parkinson's Disease: which cell type wins the race?
    Meyer AK; Maisel M; Hermann A; Stirl K; Storch A
    J Neurol Sci; 2010 Feb; 289(1-2):93-103. PubMed ID: 19733367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Induced pluripotent stem (iPS) cell-based cell therapy for muscular dystrophy: current progress and future prospects].
    Nishiyama T; Takeda S
    Brain Nerve; 2012 Jan; 64(1):39-46. PubMed ID: 22223500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pluripotent stem cells as new drugs? The example of Parkinson's disease.
    Preynat-Seauve O; Burkhard PR; Villard J; Zingg W; Ginovart N; Feki A; Dubois-Dauphin M; Hurst SA; Mauron A; Jaconi M; Krause KH
    Int J Pharm; 2009 Nov; 381(2):113-21. PubMed ID: 19782880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neural stem cells and Parkinson's disease.
    Storch A; Schwarz J
    J Neurol; 2002 Oct; 249 Suppl 3():III/30-2. PubMed ID: 12522569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of induced pluripotent stem cells into functional oligodendrocytes.
    Czepiel M; Balasubramaniyan V; Schaafsma W; Stancic M; Mikkers H; Huisman C; Boddeke E; Copray S
    Glia; 2011 Jun; 59(6):882-92. PubMed ID: 21438010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuronal cell replacement in Parkinson's disease.
    Hedlund E; Perlmann T
    J Intern Med; 2009 Oct; 266(4):358-71. PubMed ID: 19765180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.
    Chen LW; Kuang F; Wei LC; Ding YX; Yung KK; Chan YS
    CNS Neurol Disord Drug Targets; 2011 Jun; 10(4):449-58. PubMed ID: 21495962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells.
    Zhou W; Freed CR
    Stem Cells; 2009 Nov; 27(11):2667-74. PubMed ID: 19697349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research for cell therapy by induced pluripotent stem cell].
    Sakurai H; Yamanaka S
    Nihon Rinsho; 2011 Dec; 69(12):2114-8. PubMed ID: 22242307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPS cell technology-based research for the treatment of diabetic nephropathy.
    Osafune K
    Semin Nephrol; 2012 Sep; 32(5):479-85. PubMed ID: 23062989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
    Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
    Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [iPS cell therapy for Parkinson's disease].
    Takahashi J
    Rinsho Ketsueki; 2016 Aug; 57(8):1080-6. PubMed ID: 27599427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and criteria of embryonic stem and induced pluripotent stem cells for a dopamine replacement therapy.
    Cooper O; Parmar M; Isacson O
    Prog Brain Res; 2012; 200():265-76. PubMed ID: 23195423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.